Xiaoming Huang

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Yunpeng Yang, Song Qu, Jingao Li et al. · The Lancet Oncology · 2021 · 429 citations

Medicine, Clinical Trials, Immune Checkpoint Inhibitor +8

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

Yunpeng Yang, Jianji Pan, Hui Wang et al. · Cancer Cell · 2023 · 191 citations · Full text

R/m Npc, Immunology, Pathology +16

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Lin Shen, Jun Guo, Qingyuan Zhang et al. · Journal for ImmunoTherapy of Cancer · 2020 · 159 citations · Full text

Diagnosis and Management of Skull Base Osteoradionecrosis After Radiotherapy for Nasopharyngeal Carcinoma

Xiaoming Huang, Yiqing Zheng, Xiang Zhang et al. · The Laryngoscope · 2006 · 120 citations

Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models

Liangping Su, Yitian Chen, Cheng Huang et al. · Science Translational Medicine · 2023 · 108 citations

Apoptosis, Cell Death, Cancer Biology +16